Private equity firm GTCR and management partner Gregory Lucier have acquired and merged Surgical Specialties Corp. and the TachoSil Fibrin Sealant Patch to create a new company called Corza Medical.
Surgical Specialties is a medical technology company focused on surgical sutures and ophthalmic knives. TachoSil, previously owned by Takeda Pharmaceutical Co. Ltd., is a surgical patch product line used to enable bleeding control during surgeries.
The company will be led by executive chairman Gregory Lucier and CEO Dan Croteau, with a global team of over 1,700 employees supporting clinicians, distributors and medical device companies. Corza Medical will provide healthcare professionals a platform of surgical technologies with brands including Quill barbed sutures, Sharpoint Plus and Look surgical sutures, Sharpoint ophthalmic knives, and the TachoSil fibrin sealant patch.
Corza Medical will be headquartered in Westwood, MA, and operate in 13 countries throughout North America, Europe, and Asia, with manufacturing facilities in the U.S., Mexico, England, Germany, and China.
Barclays acted as financial advisor and Kirkland & Ellis acted as legal advisor to GTCR in this transaction.